These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 25639900)
1. Exceptions to the rule: case studies in the prediction of pathogenicity for genetic variants in hereditary cancer genes. Rosenthal ET; Bowles KR; Pruss D; van Kan A; Vail PJ; McElroy H; Wenstrup RJ Clin Genet; 2015 Dec; 88(6):533-41. PubMed ID: 25639900 [TBL] [Abstract][Full Text] [Related]
2. Characterization of BRCA1 and BRCA2 splicing variants: a collaborative report by ENIGMA consortium members. Thomassen M; Blanco A; Montagna M; Hansen TV; Pedersen IS; Gutiérrez-Enríquez S; Menéndez M; Fachal L; Santamariña M; Steffensen AY; Jønson L; Agata S; Whiley P; Tognazzo S; Tornero E; Jensen UB; Balmaña J; Kruse TA; Goldgar DE; Lázaro C; Diez O; Spurdle AB; Vega A Breast Cancer Res Treat; 2012 Apr; 132(3):1009-23. PubMed ID: 21769658 [TBL] [Abstract][Full Text] [Related]
3. Development and validation of a new algorithm for the reclassification of genetic variants identified in the BRCA1 and BRCA2 genes. Pruss D; Morris B; Hughes E; Eggington JM; Esterling L; Robinson BS; van Kan A; Fernandes PH; Roa BB; Gutin A; Wenstrup RJ; Bowles KR Breast Cancer Res Treat; 2014 Aug; 147(1):119-32. PubMed ID: 25085752 [TBL] [Abstract][Full Text] [Related]
4. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH. Joosse SA; Brandwijk KI; Devilee P; Wesseling J; Hogervorst FB; Verhoef S; Nederlof PM Breast Cancer Res Treat; 2012 Apr; 132(2):379-89. PubMed ID: 20614180 [TBL] [Abstract][Full Text] [Related]
5. Clinical Variant Classification: A Comparison of Public Databases and a Commercial Testing Laboratory. Gradishar W; Johnson K; Brown K; Mundt E; Manley S Oncologist; 2017 Jul; 22(7):797-803. PubMed ID: 28408614 [TBL] [Abstract][Full Text] [Related]
6. BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance. Eccles DM; Mitchell G; Monteiro AN; Schmutzler R; Couch FJ; Spurdle AB; Gómez-García EB; Ann Oncol; 2015 Oct; 26(10):2057-65. PubMed ID: 26153499 [TBL] [Abstract][Full Text] [Related]
7. Pathogenicity evaluation of BRCA1 and BRCA2 unclassified variants identified in Portuguese breast/ovarian cancer families. Santos C; Peixoto A; Rocha P; Pinto P; Bizarro S; Pinheiro M; Pinto C; Henrique R; Teixeira MR J Mol Diagn; 2014 May; 16(3):324-34. PubMed ID: 24607278 [TBL] [Abstract][Full Text] [Related]
9. Clinical relevance of rare germline sequence variants in cancer genes: evolution and application of classification models. Spurdle AB Curr Opin Genet Dev; 2010 Jun; 20(3):315-23. PubMed ID: 20456937 [TBL] [Abstract][Full Text] [Related]
10. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment. Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727 [TBL] [Abstract][Full Text] [Related]
11. A high proportion of DNA variants of BRCA1 and BRCA2 is associated with aberrant splicing in breast/ovarian cancer patients. Sanz DJ; Acedo A; Infante M; Durán M; Pérez-Cabornero L; Esteban-Cardeñosa E; Lastra E; Pagani F; Miner C; Velasco EA Clin Cancer Res; 2010 Mar; 16(6):1957-67. PubMed ID: 20215541 [TBL] [Abstract][Full Text] [Related]
12. Variant classification changes over time in BRCA1 and BRCA2. Mighton C; Charames GS; Wang M; Zakoor KR; Wong A; Shickh S; Watkins N; Lebo MS; Bombard Y; Lerner-Ellis J Genet Med; 2019 Oct; 21(10):2248-2254. PubMed ID: 30971832 [TBL] [Abstract][Full Text] [Related]
13. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer. Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241 [TBL] [Abstract][Full Text] [Related]
14. Intronic variants in BRCA1 and BRCA2 that affect RNA splicing can be reliably selected by splice-site prediction programs. Vreeswijk MP; Kraan JN; van der Klift HM; Vink GR; Cornelisse CJ; Wijnen JT; Bakker E; van Asperen CJ; Devilee P Hum Mutat; 2009 Jan; 30(1):107-14. PubMed ID: 18693280 [TBL] [Abstract][Full Text] [Related]
15. MARGINAL: An Automatic Classification of Variants in Karalidou V; Kalfakakou D; Papathanasiou A; Fostira F; Matsopoulos GK Biomolecules; 2022 Oct; 12(11):. PubMed ID: 36358902 [TBL] [Abstract][Full Text] [Related]
16. Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions: implications for prediction of pathogenicity. Walker LC; Whiley PJ; Couch FJ; Farrugia DJ; Healey S; Eccles DM; Lin F; Butler SA; Goff SA; Thompson BA; Lakhani SR; Da Silva LM; ; Tavtigian SV; Goldgar DE; Brown MA; Spurdle AB Hum Mutat; 2010 Jun; 31(6):E1484-505. PubMed ID: 20513136 [TBL] [Abstract][Full Text] [Related]
17. RNA analysis of eight BRCA1 and BRCA2 unclassified variants identified in breast/ovarian cancer families from Spain. Campos B; Díez O; Domènech M; Baena M; Balmaña J; Sanz J; Ramírez A; Alonso C; Baiget M Hum Mutat; 2003 Oct; 22(4):337. PubMed ID: 12955719 [TBL] [Abstract][Full Text] [Related]
18. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia. Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900 [TBL] [Abstract][Full Text] [Related]
19. Secondary findings in genes related to cancer phenotypes in Turkish exome sequencing data from 2020 individuals. Demir O; Saglam KA; Yilmaz M; Apuhan T; Cebi AH; Turkyilmaz A Am J Med Genet A; 2024 Nov; 194(11):e63806. PubMed ID: 38940262 [TBL] [Abstract][Full Text] [Related]
20. Quantifying prediction of pathogenicity for within-codon concordance (PM5) using 7541 functional classifications of BRCA1 and MSH2 missense variants. Loong L; Cubuk C; Choi S; Allen S; Torr B; Garrett A; Loveday C; Durkie M; Callaway A; Burghel GJ; Drummond J; Robinson R; Berry IR; Wallace A; Eccles DM; Tischkowitz M; Ellard S; Ware JS; Hanson H; Turnbull C; Genet Med; 2022 Mar; 24(3):552-563. PubMed ID: 34906453 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]